Mechanisms of immunogenicity in colorectal cancer

Abstract

Background The immune response in cancer is increasingly understood to be important in determining clinical outcomes, including responses to cancer therapies. New insights into the mechanisms underpinning the immune microenvironment in colorectal cancer are helping to develop the role of immunotherapy and suggest targeted approaches to the management of colorectal cancer at all disease stages. Method A literature search was performed in PubMed, MEDLINE and Cochrane Library databases to identify relevant articles. This narrative review discusses the current understanding of the contributors to immunogenicity in colorectal cancer and potential applications for targeted therapies. Results Responsiveness to immunotherapy in colorectal cancer is non‐uniform. Several factors, both germline and tumour‐related, are potential determinants of immunogenicity in colorectal cancer. Current approaches target tumours with high immunogenicity driven by mutations in DNA mismatch repair genes. Recent work suggests a role for therapies that boost the immune response in tumours with low immunogenicity. Conclusion With the development of promising therapies to boost the innate immune response, there is significant potential for the expansion of the role of immunotherapy as an adjuvant to surgical treatment in colorectal cancer.

FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2

“…Colorectal cancer (CRC) is associated with somatic mutational and epigenetic events affecting tumor development and the host immune system [1]. As a disease affecting the digestive tract from the colon to the rectum, CRC typically starts with polyps in the digestive tract which gradually enlarge, attract blood vessels, and become metastatic to spread to other tissues [2].…”

Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm

“…It is well-recognized that the progression and recurrence of cancer is not just regulated by the genomic mutations inherent to malignant cells but also by host and immunological responses (120). Various mechanisms in the TIME may stimulate a pro-tumorigenic environment and disease progression.…”

The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies

“…When an inflammatory insult persists, mechanisms of immune surveillance may fail, with the concurrent recruitment of immunoregulatory cells [36], including myeloid-derived suppressor cells (MDSCs), T regulatory (Treg) cells, type 2 macrophages, and other cancer-associated cell types [37], that altogether sustain tumor cell growth [27]. Additionally, in intestinal mucosa with prolonged inflammation, neutrophils continuously accumulate.…”